Protective Effects of Atorvastatin on Chronic Allograft Nephropathy in Rats

Journal of Surgical Research

Volumn 143, Issue 2, 2007, Pages 428-436

  Zhang, Wei ^a   Liu, Min ^a   Wu, Yichao ^b   Zhu, Pengcheng ^b   Yin, Changjun ^a   Gu, Min ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

atorvastatin; chronic allograft nephropathy; fibrosis; kidney transplantation

Indexed keywords

ATORVASTATIN; CD68 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 3; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; ATTENUATION; CELL INFILTRATION; CHRONIC ALLOGRAFT NEPHROPATHY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY TUBULE; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZATION; RAT; RNA ANALYSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHEMOKINES; CHRONIC DISEASE; CYCLOSPORINE; CYTOKINES; DRUG THERAPY, COMBINATION; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GENE EXPRESSION; GRAFT REJECTION; HEPTANOIC ACIDS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MONOCYTES; PROTEINURIA; PYRROLES; RATS; RATS, INBRED F344; RATS, INBRED LEW; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 36048929854     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.12.557     Document Type: Article

References (42)

1. Paul L.C. Chronic allograft nephropathy: An update. Kidney Int 56 (1999) 783
2. Yehia M., Matheson P.J., Merrilees M.J., et al. Predictors of chronic allograft nephropathy from protocol biopsies using histological and immunohistochemical techniques. Nephrology (Carlton) 11 (2006) 261
3. Shimizu A., Yamada K., Sachs D.H., et al. Mechanisms of chronic renal allograft rejection. II. Progressive allograft glomerulopathy in miniature swine. Lab Invest 82 (2002) 673
4. Langham R.G., Egan M.K., Dowling J.P., et al. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 72 (2001) 1826
5. Li C., Lim S.W., Choi B.S., et al. Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 25 (2005) 611
6. Goicoechea M., de Vinuesa S.G., Lahera V., et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 17 (2006) S231
7. Collins P., Ford I., Croal B., et al. Haemostasis, inflammation and renal function following exercise in patients with intermittent claudication on statin and aspirin therapy. Thromb J 4 (2006) 9
8. Muhlestein J.B., May H.T., Jensen J.R., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48 (2006) 396
9. Kinderlerer A.R., Steinberg R., Johns M., et al. Statin-induced expression of CD59 on vascular endothelium in hypoxia: A potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res Ther 8 (2006) R130
10. Yilmaz A., Reiss C., Weng A., et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 79 (2006) 529
11. Li C., Yang C.W., Park J.H., et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286 (2004) F46
12. Li C., Sun B.K., Lim S.W., et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 79 (2005) 1522
13. Liu M., Wu Y.C., Zhang W., et al. Effect of atorvastatin on intrarenal osteopontin expression in rat allogeneic kidney transplantation. Chin J Clin Rehab (2006) (in press).
14. Fisher B., and Lee S. Microvascular surgical techniques in research, with special reference to renal transplantation in the rat. Surgery 58 (1965) 904
15. Xu Z.K., Liu X.L., Zhang W., et al. Establishment of a pig model of combined pancreas-kidney transplantation. World J Gastroenterol 5 (1999) 172
16. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713
17. McCarthy G.P., and Roberts I.S. Diagnosis of acute renal allograft rejection: Evaluation of the Banff 97 Guidelines for Slide Preparation. Transplantation 73 (2002) 1518
18. Pfaffl M.W., Horgan G.W., and Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30 (2002) e36
19. Wu Y., Liu Z., Xiang Z., et al. Obesity-related glomerulopathy: Insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147 (2006) 44
20. Yates P.J., and Nicholson M.L. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 16 (2006) 148
21. Casey R.G., Joyce M., Roche-Nagle G., et al. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 123 (2005) 176
22. Kandoussi A., Martin F., Hazzan M., et al. HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin Sci (Lond) 103 (2002) s81
23. Mizuguchi Y., Miyajima A., Kosaka T., et al. Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J Urol 172 (2004) 2456
24. Sabbatini M., Pisani A., Uccello F., et al. Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol 15 (2004) 901
25. Kobashigawa J.A. Statins in solid organ transplantation: Is there an immunosuppressive effect?. Am J Transplant 4 (2004) 1013
26. Jiang H., Yang X.F., Wynn C., et al. IL-10: A tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. Transplant Proc 33 (2001) 510
27. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736
28. Arnaud C., Braunersreuther V., and Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15 (2005) 202
29. Blanco-Colio L.M., Tunon J., Martin-Ventura J.L., et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63 (2003) 12
30. Kobashigawa J.A. Statins and cardiac allograft vasculopathy after heart transplantation. Semin Vasc Med 4 (2004) 401
31. Lawman S., Mauri C., Jury E.C., et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 173 (2004) 7641
32. Geissler I., Collins L., Schofield R., et al. In vivo suppression of major histocompatibility complex class II expression on porcine vascular endothelial cells by an HMG-CoA reductase inhibitor. Transplantation 81 (2006) 922
33. Raggatt L.J., and Partridge N.C. HMG-CoA reductase inhibitors as immunomodulators: Potential use in transplant rejection. Drugs 62 (2002) 2185
34. Steffens S., and Mach F. Drug insight: Immunomodulatory effects of statins-potential benefits for renal patients?. Nat Clin Pract Nephrol 2 (2006) 378
35. Li Y., Koster T., Morike C., et al. Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation. Eur J Cardiothorac Surg 30 (2006) 515
36. Spriewald B.M., Ensminger S.M., Billing J.S., et al. Increased expression of transforming growth factor-beta and eosinophil infiltration is associated with the development of transplant arteriosclerosis in long-term surviving cardiac allografts. Transplantation 76 (2003) 1105
37. Chen H.C., Guh J.Y., Shin S.J., et al. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 160 (2002) 141
38. Wada T., Azuma H., Furuichi K., et al. Reduction in chronic allograft nephropathy by inhibition of p38 mitogen-activated protein kinase. Am J Nephrol 26 (2006) 319
39. Chen J.C., Huang K.C., and Lin W.W. HMG-CoA reductase inhibitors up-regulate heme oxygenase1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 18 (2006) 32
40. Ejiri J., Inoue N., Tsukube T., et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: Protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 59 (2003) 988
41. Turner N.A., O'Regan D.J., Ball S.G., et al. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 19 (2005) 804
42. Otto A., Fontaine J., Tschirhart E., et al. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: Implication of the NAD(P)H oxidase pathway. Br J Pharmacol 148 (2006) 544